SK Biopharmaceuticals (KRX:326030) signed a pharmaceutical supply contract worth 99.4 billion won with its US subsidiary, SK Life Science, according to a Tuesday filing with the Korean Exchange.
The contract is to supply its epilepsy treatment cenobamate, which is sold in the US market under the brand name, XCOPRI.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.